Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbapenem De-escalation for ESBL-PE Infections (CARBEPARGNE)
NCT02265445Phase 4Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2015
- Primary completion
- Jun 2016
01
Overview
Phase 4, randomised, open-label trial in Enterobacteriaceae infection, urinary tract infection (UTI), biliary tract infection and 1 more, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical response. Started Jun 2015; status: terminated.
02
Conditions
Enterobacteriaceae infectionurinary tract infection (UTI)biliary tract infectiongastrointestinal infection
Beyond the preview
Go deeper on NCT02265445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265445.